US pharmaceutical company Lilly will invest $50 million in expanding its plant in Alcobendas (Madrid) between 2025 and 2026. $30 million of this will be used to start up two new packaging lines, in addition to the three existing ones. The remaining $20 million will go on additional investments.

The Managing Director in Spain, Christina Vega, shared this information in a meeting with the media in which she detailed these investments.

Investment in R&D
The Lilly complex in Alcobendas includes the company's offices, the headquarters for the Lilly Foundation, a production plant and an R&D centre, one of the biggest of its eight worldwide. Opened in 2002 and expanded in 2009, the company describes it as the most important and comprehensive private R&D centre in the Spanish pharmaceutical industry. In 2023 it was announced that 167 million euros would be invested in this facility by 2027.

Thanks to this laboratory and production centre, Lilly is one of the few companies that cover the entire drug development process in Spain, from synthesis to distribution. Medicines are exported from the Madrid plant to over 120 countries.

Last year, the Spanish subsidiary expanded its workforce by around 100 people, from 1,100 to 1,200 employees, 900 of whom work in Madrid. The R&D centre has grown from 100 to 120 employees over the last four years.

^{Photo: Lilly}